BOVINE RESPIRATORY SYNCYTIAL VIRUS AS A HUMAN VACCINE

尽管经过三十年的努力， 针对呼吸道合胞病毒（RSV），最重要的原因， 世界各地的婴儿肺病。牛呼吸道合胞病毒 （BRSV）与RSV抗原性相关，不会导致 实验室动物，并赋予高度显着的保护，防止RSV 血清阴性动物感染。它似乎不会引起 与以前的候选疫苗不同。因为几乎所有 RSV疫苗的潜在接种者将是患有RSV病毒的婴儿 大量的母源性RSV抗体，因为 这种抗体已经显示出阻断其它候选药物的功效 疫苗，这项建议的具体目的是测试效力， BRSV在先前给予人RSV抗体的棉鼠中的安全性 其含量相当于人类婴儿的含量。如果BRSV保护 针对RSV在这些条件下，后续研究将包括 临床试验

Despite efforts spanning three decades, there is no licensed vaccine against respiratory syncytial virus (RSV), the most important cause of infant pulmonary disease worldwide. Bovine respiratory syncytial virus (BRSV) is antigenically related to RSV, causes no significant pathology in laboratory animals, and confers highly significant protection against RSV infection in seronegative animals. It appears not to cause potentiated disease, unlike previous candidate vaccines. Because virtually all potential recipients of an RSV vaccine would be infants possessing substantial amounts of maternally derived antibody to RSV, and because such antibody has been shown to block the efficacy of other candidate vaccines, the specific aim of this proposal is to test the efficacy and safety of BRSV in cotton rats previously administered human RSV antibody in amounts equivalent to those seen in human infants. If BRSV protects against RSV under these conditions, followup studies would include clinical trials.